Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

When surgeons dissect tissue to remove a tumor or make a repair, they must work cautiously, relying on electrophysical ...

In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ...

Inhibiting an overabundant enzyme saved a key component of a brain signaling pathway that is vital for motor control in a ...

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with ...

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA proof-of-concept study (NCT05560646) was evaluating Organon’s therapy, ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 ...

Peter Moulding joined a clinical trial for the drug AMP945 not really knowing whether it would help him with deadly stage ...

The combination of climate change and pathogen expansion could be fueling a surge in infectious diseases. GEN consulted ...

A research team, led by Professor Lin Xiang (first right) and Professor Shen Jiangang (second right), has discovered that ...